CAR-T cell therapy has increased in its popularity due to its robust nature and being MHC-independent. In this webinar, Dr. Rogier Reijmers, Principal Scientist at LUMICKS, will present several case studies and demonstrate how measuring cell avidity provides new insights by providing a more complete and physiologically relevant picture of the interaction between cells and their targets.
Key learning points:
- The overall binding strength (or avidity) between CAR T cells and the target cells is a crucial parameter for identifying and developing potent cancer immunotherapies and understanding the underlying mechanisms.
- Cell avidity outcomes correlate with other in vitro assays and in vivo outcomes.
- The z-Movi® Cell Avidity Analyzer is a novel and unique instrument for direct measurement of cell–cell interaction strength using acoustic forces, providing predictive, reproducible and fast results at a single-cell level.
